Abstract | BACKGROUND: The absolute benefit of drug-eluting stents (DES) in low-risk patients and lesions is not well established. HYPOTHESIS: METHODS: This study assessed and compared 2-year clinical outcomes of 304 consecutive patients (147 BMS patients and 157 DES patients) treated with a single coronary stent (4.0 mm) for single de novo large coronary artery disease in 3 referral cardiac centers. The primary outcome was a composite of major adverse cardiac events at 2 years after the index procedure. RESULTS: The reference vessel diameter was similar in both groups (3.92 ± 0.29 mm in BMS vs 3.95 ± 0.24 mm in DES, P = 0.50). Late loss was larger in the BMS group (1.04 ± 0.83 mm vs 0.73 ± 0.91 mm in DES, P = 0.03). The incidence of major adverse cardiac events at the 2-year clinical follow-up was very low, 24 of 304 patients (7.9%), regardless of stent type deployed (7.5% in BMS vs 8.3% in DES, P = 0.83). The rate of target vessel revascularization was also similar in both groups (4.8% in BMS vs 5.7% in DES, P = 0.80). CONCLUSIONS: Two-year clinical outcomes after PCI with a single large coronary stent (4.0 mm) were excellent. The clinical outcomes were not affected by the type of stent used.
|
Authors | Hyun-Tae Kim, Chang-Wook Nam, Seung-Ho Hur, Kwon-Bae Kim, Sang-Hee Lee, Geu-Ru Hong, Jong-Seon Park, Young-Jo Kim, Ung Kim, Tae-Hyun Yang, Doo-Il Kim, Dong-Soo Kim |
Journal | Clinical cardiology
(Clin Cardiol)
Vol. 33
Issue 10
Pg. 620-625
(Oct 2010)
ISSN: 1932-8737 [Electronic] United States |
PMID | 20960536
(Publication Type: Comparative Study, Journal Article, Multicenter Study)
|
Copyright | © 2010 Wiley Periodicals, Inc. |
Chemical References |
- Tubulin Modulators
- zotarolimus
- Paclitaxel
- Sirolimus
|
Topics |
- Coronary Angiography
- Coronary Stenosis
(diagnostic imaging, surgery)
- Drug-Eluting Stents
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Paclitaxel
(pharmacology)
- Postoperative Period
- Prosthesis Design
- Retrospective Studies
- Severity of Illness Index
- Sirolimus
(analogs & derivatives, pharmacology)
- Time Factors
- Treatment Outcome
- Tubulin Modulators
(pharmacology)
|